Pfenex to Participate at the JMP Securities Life Sciences Conference
June 05 2019 - 4:05PM
Pfenex Inc. (NYSE American: PFNX) a clinical-stage development and
licensing biotechnology company focused on leveraging its Pfēnex
Expression Technology® to improve protein therapies for unmet
patient needs, announced today that Eef Schimmelpennink, Chief
Executive Officer, will be presenting a corporate overview at the
JMP Securities Life Sciences Conference, taking place June 19-20 at
The St. Regis New York hotel in New York City.
Presentation Details:Date:
Wednesday, June 19, 2019Time: 12:30pm Eastern
Time
Interested parties can access the live audio webcast and archive
from the Investors Section of Pfenex's website at
www.pfenex.com.
About Pfenex Inc.Pfenex is a clinical-stage
development and licensing biotechnology company focused on
leveraging its Pfēnex Expression Technology® to develop and improve
protein therapies for unmet patient needs. Using the patented
Pfēnex Expression Technology platform, the Company has created an
advanced pipeline of potential therapeutic equivalents, novel
biologics, vaccine and vaccine components, and biosimilars. The
Company’s lead product candidate is PF708, under development as a
therapeutic equivalent drug candidate to Forteo® (teriparatide)
indicated for the treatment of osteoporosis. In addition, the
Company is developing hematology/oncology products, including
PF743, a recombinant crisantaspase, and PF745, a recombinant
crisantaspase with half-life extension, in collaboration with Jazz
Pharmaceuticals Ireland Limited (Jazz). Both PF743 and PF745
are being developed for the treatment of Acute Lymphoblastic
Leukemia (ALL). We also use our Pfēnex Expression Technology
platform to produce CRM197, a diphtheria toxoid carrier protein
used in prophylactic and therapeutic vaccine candidates under
development by third parties.
Pfenex investors and others should note that we announce
material information to the public about the Company through a
variety of means, including our website (http://www.pfenex.com/),
our investor relations website (http://pfenex.investorroom.com/),
press releases, SEC filings, public conference calls, corporate
Twitter account (https://twitter.com/pfenex), Facebook page
(https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/),
and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in
order to achieve broad, non-exclusionary distribution of
information to the public and to comply with our disclosure
obligations under Regulation FD. We encourage our investors and
others to monitor and review the information we make public in
these locations as such information could be deemed to be material
information. Please note that this list may be updated from time to
time.
Company Contact: Susan A. KnudsonChief
Financial Officer(858) 352-4324sknudson@pfenex.com
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pfenex (AMEX:PFNX)
Historical Stock Chart
From Apr 2023 to Apr 2024